文献速递糖尿病肥胖与代谢综合征

司美格鲁肽对超重或肥胖但无糖尿病者血糖回归与进展的影响:SELECT试验

Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
PubMed 文献 · Diabetes Care · 2024-01-01

SELECT试验为多中心双盲研究,纳入17,604例有心血管疾病且超重或肥胖但无糖尿病者,随机接受司美格鲁肽2.4 mg每周皮下注射或安慰剂。司美格鲁肽增加血糖回归至正常(第156周69.5% vs 35.8%),减少进展为生化糖尿病(1.5% vs 6.9%),但未减缓长期血糖进展。

要点

  • 司美格鲁肽组第156周血糖正常比例69.5%,安慰剂组35.8%。
  • 司美格鲁肽组第156周生化糖尿病比例1.5%,安慰剂组6.9%。
  • 预防一例糖尿病需治疗18.5例;体重降低介导24.5%的进展和27.1%的回归。

核心结论

  • 在有心血管疾病且超重或肥胖但无糖尿病者中,长期司美格鲁肽增加血糖回归至正常并减少进展为生化糖尿病,但未减缓血糖随时间进展。

研究设计与样本

  • 多中心、双盲试验,纳入年龄≥45岁、BMI≥27 kg/m2、有心血管疾病但无糖尿病(HbA1c<6.5%)者,随机接受司美格鲁肽2.4 mg每周皮下注射或安慰剂;共17,604例,司美格鲁肽组8,803例,安慰剂组8,801例。

主要发现

  • 平均±SD干预暴露152±56周,随访176±40周;两治疗组HbA1c最低值均在第20周。
  • 此后HbA1c在两组相似上升,平均差异为-0.32个百分点(95% CI -0.33至-0.30;-3.49 mmol/mol [-3.66至-3.32]),差异在整个研究中有利于司美格鲁肽(P < 0.0001)。
  • 体重在第65周进入平台期,司美格鲁肽组低8.9%。
  • 第156周时,司美格鲁肽组血糖正常比例更高(69.5% vs 35.8%;P < 0.0001),生化糖尿病比例更低(1.5% vs 6.9%;P < 0.0001)。
  • 预防一例糖尿病需治疗18.5例;回归和进展均取决于基线血糖,体重降低幅度介导24.5%的进展和27.1%的回归。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH DESIGN AND METHODS: In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo. Major glycemic outcomes were HbA1c and proportions achieving biochemical normoglycemia (HbA1c <5.7%) and progressing to biochemical diabetes (HbA1c ≥6.5%). RESULTS: Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo. Mean ± SD intervention exposure was 152 ± 56 weeks and follow-up 176 ± 40 weeks. In both treatment arms mean nadir HbA1c for participants was at 20 weeks. Thereafter, HbA1c increased similarly in both arms, with a mean difference of -0.32 percentage points (95% CI -0.33 to -0.30; -3.49 mmol/mol [-3.66 to -3.32]) and with the difference favoring semaglutide throughout the study (P < 0.0001). Body weight plateaued at 65 weeks and was 8.9% lower with semaglutide. At week 156, a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001) and a smaller proportion had biochemical diabetes by week 156 (1.5% vs. 6.9%; P < 0.0001). The number needed to treat was 18.5 to prevent a case of diabetes. Both regression and progression were dependent on glycemia at baseline, with the magnitude of weight reduction important in mediating 24.5% of progression and 27.1% of regression. CONCLUSIONS: In people with preexisting cardiovascular disease and overweight or obesity but without diabetes, long-term semaglutide increases regression to biochemical normoglycemia and reduces progression to biochemical diabetes but does not slow glycemic progression over time.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kahn SE, Deanfield JE, Jeppesen OK, et al. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care. 2024. PMID: 38907683. doi:10.2337/dc24-0491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。